In May, Solid had the honor of participating in the 8th European Conference on Rare Diseases & Orphan Products in Edinburgh, which is organized bi-annually by the European Organisation for Rare Diseases (EURODIS) and DIA Europe, Middle East & Africa.
ECRD is one of the foremost meetings of the rare disease community, offering those impacted by rare diseases and those committed to solving them with the opportunity to share ideas, concerns and progress.
During the meeting, Carl Morris, Ph.D., Solid’s vice president of Research & Development, showcased why Solid fits naturally into the conference’s theme of “Game Changers in Rare Disease.” During a panel discussion called “Launch Platforms,” Dr. Morris discussed Solid’s unique business model that focuses solely on solving Duchenne muscular dystrophy, regardless of technology or modality. Dr. Morris also discussed our novel strategies to partner with the community and develop tested collaborations.
“It is through working together, sharing our learnings and progress, and listening to the experiences of others that we will be successful in our goal to address all facets of Duchenne muscular dystrophy and improve the quality of life for those impacted by the disease,” said Dr. Morris.
To learn more about our approach to therapy and assistive device development,